Fmr LLC Has $152.63 Million Holdings in Phreesia, Inc. (NYSE:PHR)

FMR LLC lowered its holdings in Phreesia, Inc. (NYSE:PHR - Free Report) by 0.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,697,395 shares of the company's stock after selling 44,054 shares during the quarter. FMR LLC owned 11.59% of Phreesia worth $152,634,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of PHR. Champlain Investment Partners LLC boosted its stake in Phreesia by 4.1% during the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company's stock valued at $57,062,000 after buying an additional 97,847 shares during the last quarter. TimesSquare Capital Management LLC boosted its position in Phreesia by 2.3% during the 3rd quarter. TimesSquare Capital Management LLC now owns 868,409 shares of the company's stock valued at $19,791,000 after acquiring an additional 19,395 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Phreesia by 3.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 447,239 shares of the company's stock worth $10,193,000 after purchasing an additional 16,112 shares in the last quarter. Peregrine Capital Management LLC raised its stake in Phreesia by 11.3% in the 2nd quarter. Peregrine Capital Management LLC now owns 354,607 shares of the company's stock worth $7,518,000 after acquiring an additional 36,047 shares during the last quarter. Finally, Squarepoint Ops LLC raised its stake in Phreesia by 56.3% in the 2nd quarter. Squarepoint Ops LLC now owns 250,396 shares of the company's stock worth $5,308,000 after acquiring an additional 90,215 shares during the last quarter. Hedge funds and other institutional investors own 92.10% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PHR. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 price objective on shares of Phreesia in a report on Thursday, September 5th. JPMorgan Chase & Co. boosted their target price on Phreesia from $27.00 to $28.00 and gave the stock an "overweight" rating in a report on Monday, September 9th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $34.00 price target on shares of Phreesia in a research report on Thursday, September 5th. Truist Financial boosted their target price on Phreesia from $29.00 to $31.00 and gave the company a "buy" rating in a research report on Friday, September 6th. Finally, JMP Securities reissued a "market outperform" rating and issued a $30.00 target price on shares of Phreesia in a research report on Thursday, September 5th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, Phreesia currently has an average rating of "Moderate Buy" and an average price target of $29.42.

Phreesia Stock Up 1.3 %

Phreesia stock traded up $0.28 during trading hours on Wednesday, hitting $21.18. The company had a trading volume of 401,625 shares, compared to its average volume of 445,204. The firm has a market capitalization of $1.22 billion, a P/E ratio of -11.77 and a beta of 0.98. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.77 and a quick ratio of 1.77. The firm's fifty day moving average is $20.32 and its 200-day moving average is $21.79. Phreesia, Inc. has a fifty-two week low of $14.55 and a fifty-two week high of $29.16.

Phreesia (NYSE:PHR - Get Free Report) last posted its earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.06. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. The business had revenue of $102.12 million for the quarter, compared to analyst estimates of $101.76 million. On average, research analysts forecast that Phreesia, Inc. will post -1.23 earnings per share for the current year.

Insider Activity at Phreesia

In related news, SVP David Linetsky sold 1,716 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total transaction of $39,897.00. Following the transaction, the senior vice president now directly owns 203,318 shares in the company, valued at approximately $4,727,143.50. The trade was a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Chaim Indig sold 5,295 shares of the company's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total transaction of $123,108.75. Following the completion of the transaction, the chief executive officer now owns 1,223,736 shares in the company, valued at approximately $28,451,862. This represents a 0.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 45,149 shares of company stock valued at $986,286 in the last ninety days. Insiders own 5.80% of the company's stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.